Pathologic Effects of Chemotherapy

  • Kurt Jellinger
Part of the Cancer Treatment and Research book series (CTAR, volume 12)


With the growing use of potent antineoplastic agents both systemic and nervous system toxicity have become a more pressing issue, and the advent of increasingly aggressive chemotherapy protocols has created a myriad of complications of cytotoxic therapy that have only recently become important. Rapidly dividing tissues, such as bone marrow and epithelial cells, are most overtly affected by such therapy; the dose in major degree, reflects the tolerance of these organs to the various agents [1, 2, 2a]. Organs with less proliferative activity, such as the central nervous system (CNS), seem less sensitive to the adverse effects of chemotherapy, although cytostatic agents may reach the CNS directly by intrathecal (IT) injections or indirectly via the vasculature in patients treated with oral or parenteral medication.


Malignant Glioma Acute Leukemia Measle Virus Childhood Leukemia Prophylactic Cranial Irradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Guarino AM: Pharmacologic and toxicologic studies of anticancer drugs. In: DeVita VT, Busch H (eds) Methods in Cancer Research, Vol. 17, Cancer Drug Development, New York: Academic Press 1979, pp 91–176.Google Scholar
  2. 2.
    Crooke ST, Prestayko AW: Cancer and chemotherapy. Vol. 3: Antineoplastic agents. New York: Academic Press, 1981.Google Scholar
  3. 2a.
    Dort RT, Fritz WL: Cancer, chemotherapy handbook. New York: Elsevier-North Holland, 1980.Google Scholar
  4. 3.
    Allen JC: The effect of cancer therapy on the nervous system. J Pediatr 93 (6): 903–909, 1978.PubMedGoogle Scholar
  5. 3a.
    Young DF, Posner JB: Nervous system toxicity of the chemotherapeutic agents. In: Vinken PJ, Bruyn GW (eds) Handbook of Clinical Neurology, Vol. 39, North Holland: Amsterdam 1980, pp 91–129.Google Scholar
  6. 3b.
    Young DF: Neurological complications of chemotherapy. In: Silverstein A (ed.): Neurological complications of therapy. Futura Publ Comp: Mount Kisco, NY, 1982, pp 57–113.Google Scholar
  7. 4.
    Vick NA, Khandekar JD, Bigner DD: Chemotherapy of brain tumors. Arch Neurol (Chic) 34 (9): 523–526, 1977.Google Scholar
  8. 5.
    Byfield JE: Central nervous system toxicities from combined therapies. Front Radiat Ther One, vol. 13, Basel: Karger, pp 228–240, 1979.Google Scholar
  9. 5a.
    Young RC, Ozols RF, Myers CE: The anthracycline antineoplastic drugs. New Engl J Med 305: 139–152, 1981.PubMedGoogle Scholar
  10. 6.
    Abelson HT: Methotrexate and central nervous system toxicity. Cancer Treat Rep 62 (8): 1999–2001, 1978.PubMedGoogle Scholar
  11. 7.
    Shapiro WR, Young DF, Mehta PM: Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. New Engl J Med 293: 161–166, 1975.PubMedGoogle Scholar
  12. 8.
    Bleyer WA, Poplack DG: Clinical studies on central nervous system pharmacology of methotrexate. In: Clinical Pharmacology of Anti-Neoplastic Drugs. Pinedo HH, Boeslma E, (ed). Amsterdam/North-Holland 1978, pp 115–131.Google Scholar
  13. 9.
    Pochedly C: Neurotoxicity due to CNS therapy for leukemia. Med Ped Oncol 3: 101–115, 1977.Google Scholar
  14. 10.
    Weiss HD, Walker MD, Wiernik PH: Neurotoxicity of common used antineoplastic agents. New Engl J Med 291:75–81, 127–133, 1974.Cancer 35: 1–39, 1977.PubMedGoogle Scholar
  15. 10a.
    Prestayko, AW, Crooke ST, Baker ST, Carter SK, Schein PS (eds) Nitrosureas. Current status and new developments. New York: Academic Press, 1981.Google Scholar
  16. 11.
    Leenhouts HP, Chadwick KH, Deen DF: An analysis of the interaction between two nitrosourea compounds and X-radiation in rat brain tumour cells. Int J Radiat Biol 37 (2): 169–181, 1980.Google Scholar
  17. 12.
    Weinkam RJ, Shiba DA: Procarbazine. In: Anticancer Drugs. Chabner B (ed). New York: B Saunders, 1978.Google Scholar
  18. 12a.
    Issels BF: The podophyllotoxin derivatives VP16-213 and VM 26. Cancer Chemother Pharmacol 7: 73–80, 1982.Google Scholar
  19. 13.
    Phillips TL, Fu KK: Acute and late effects of multimodal therapy on normal tissue. Cancer 40 (2): 489–494, 1977.PubMedGoogle Scholar
  20. 14.
    Jaffe N: Late side effects of treatment, skeletal, genetic, central nervous system, and oncogenic. Pediatr Clinics N Amer 23 (1): 233–244, 1976.Google Scholar
  21. 15.
    Ghione M: Cardiotoxic effects of antitumor agents. Cancer Chemother Pharmacol 1 (1): 25–34, 1978.Google Scholar
  22. 16.
    Engelhardt R: Kombinierte Strahlen- und Chemotherapie aus der Sicht des onkologischen Internisten. In: Kombinierte Strahlen- und Chemotherapie. Wannenmacher M (ed), München- Wien-Baltimore: Urban & Schwarzenberg 1979, pp 88–95.Google Scholar
  23. 17.
    Litam JR, Dail DH, Spitzer G, et al: Early pulmonary toxicity after administration of high-dose BCNU. Cancer Treat Rep 65 (1): 39–44, 1981.PubMedGoogle Scholar
  24. 18.
    Gale GR, Atkins LM: Cisplatin and diethyldithiocarbamate in treatment of L1210 leukemia. J Clin Hemat Oncol 11 (2): 41–45, 1981.Google Scholar
  25. 19.
    Walker MD, Green SB, Byar DP, Alexander Jr E, Batzdorf U, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. New Engl J Med 303 (51): 1323–1329, 1980.PubMedGoogle Scholar
  26. 20.
    Jellinger K, Vole D, Grisold W, Podreka I, Böck P, et al. Multimodality treatment of malignant gliomas. Zbl Neurochir 42 (2): 99–122, 1981.Google Scholar
  27. 21.
    Reagan TH, Bisel HF, Childs Jr DS, Layton DD, Rhoton AL, Taylor W: Controlled study of CCNU and radiation-therapy in malignant astrocytoma. J Neurosurg 44 (2): 186–190, 1976.PubMedGoogle Scholar
  28. 22.
    Levin VA, Wilson CB, Davis R, Wara WM, Pischer TL, Irwin L: A phase III comparison of BCNU, hydroxyurea and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. J Neurosurg 51 (4): 526–532, 1979.PubMedGoogle Scholar
  29. 23.
    Brisman H, Housepian EM, Chang CM, Duffy P: Adjuvant nitrosourea therapy for glioblastoma. Arch Neurol (Chic) 33 (11): 745–750, 1976.Google Scholar
  30. 24.
    Avellanosa AM, West CR, Tsukada Y, Highby DJ, Barshi S, Reese PA, Jennings E: Chemotherapy of nonirradiated malignant gliomas. Cancaer 44 (3): 839–846, 1979.Google Scholar
  31. 25.
    Durant JR, Norgard NJ, Murad TM, Bartolucci AA, Langford KH: Pulmonary toxicity associated with bischloroethylnitrosoureas (ECNU) Ann Intern Med 90 (2): 191–194, 1979.Google Scholar
  32. 26.
    Aronin PA, Mahaley MS, Rudnick SA, Dudka L, Donohue JD, Selker RG, Moore MN: Prediction of BCNU pulmonary toxicity in patients with malignant gliomas. New Engl J Med 303 (39): 183–188, 1980.PubMedGoogle Scholar
  33. 27.
    Harmon WE: Chronic renal failure in children treated with MethylCCNU. New Eng J Med 300: 1200–1203, 1979.PubMedGoogle Scholar
  34. 28.
    Thunold S, Moe PJ: Complications of cytostatic therapy in childhood leukemia. Acta path microbiol Scand, A Suppl 236: 84–96, 1973.Google Scholar
  35. 29.
    Schaefer STD, Wright CG, Post JD, Frenkel EP. Cis-platinum vestibular toxicity. Cancer 47 (5): 857–859, 1981.PubMedGoogle Scholar
  36. 30.
    Leventhal BG, Cohen P, Triem SC: Effect of chemotherapy on the immune response in acute leukemia. Israel J Med Sei 10 (8): 866–887, 1974.Google Scholar
  37. 31.
    Simone JV, Holland E, Johnson W: Fatalities during remission of childhood leukemia. Blood 39 (5): 759–550, 1972.PubMedGoogle Scholar
  38. 32.
    Groff P, Torhorst J, Speck B. Die Graft-versus-Host Krankheit, eine wenig bekannte Komplikation der Bluttransfusion. Schweiz Med Wschr 106: 634–639, 1976.PubMedGoogle Scholar
  39. 33.
    Woods WG, Lubin BN: Fatal graft versus host disease following a blood transfusion in a child with neuroblastoma. Pediatrics 67 (2): 217–221, 1981.PubMedGoogle Scholar
  40. 34.
    Schmidmeier W, Feil W, Gebhart W, Grisold W, Gschnait F, Hinterberger W, Höcker P, Jellinger K, et al: Fatal graft-versus-host reaction following granulocyte transfusions. Blood (in press).Google Scholar
  41. 35.
    Toland DM, Coltan CM, Hall W: Second malignancies complicating Hodgkin–s disease. Proc 13th Meet Amer Soc Clin Oncol, Vol. 18, Denver 1977.Google Scholar
  42. 36.
    Kim HD: The development of non-Hodgkin’s lymphomas following therapy for Hodgkin’s disease. Cancer 46 (6): 2596–2602, 1980.PubMedGoogle Scholar
  43. 37.
    Louie S, Schwartz RS: Immunodeficiency and pathogenesis of lymphoma and leukemia. Sem Hematol 15 (11): 117–138, 1978.Google Scholar
  44. 37a.
    Coleman CN, Burke JS, Varghese A, Rosenberg SA, Kaplan HS: Secondary leukemia and Non-Hodgkin’s lymphoma in patients treated for Hodgkin’s disease. In: Malignant Lymphomas. New York: Academic Press, 1982, pp 259–276.Google Scholar
  45. 38.
    Vogl SE: Acute leukemia complicating treatment of glioblastoma multiforme. Cancer 41 (2): 333–336, 1978.PubMedGoogle Scholar
  46. 39.
    Chung CK, Stryker JA, Cruse A, Vannucci R, Towfighi J: Glioblastoma multiforme following prophylactic cranial irradiation and intrathecal methotrexate in a child with acute lymphatic leukemia. Cancer 47 (11): 2563–2566, 1981.PubMedGoogle Scholar
  47. 39a.
    Glioblastoma multiforme in a patient with ALL who received a bone marrow transplant. Transplant Proc 14: 770–774, 1982.Google Scholar
  48. 40.
    Merker PC, Wodinsky I, Geran R: Review of selected experimental brain tumor models used in chemotherapy experiments. Cancer Chemother Rep 59 (4): 729–736, 1975.PubMedGoogle Scholar
  49. 41.
    Rosenblum ML, Knebel KD, Vaquez DA, Wilson CB: Brain tumor therapy. Quantitative analysis using a model system. J Neurosurg 46 (2): 145–154, 1977.PubMedGoogle Scholar
  50. 42.
    Paoletti P, Walker MD, Butti G, Knerich R (eds): Multidisciplinary Aspects of Brain Tumor Therapy. Amsterdam-New York: Elsevier/North-Holland, 1979.Google Scholar
  51. 43.
    Spence AM, Geraci JP: Combined cyclotron fast-neutron and BCNU therapy in a rat brain tumor model. J Neurosurg 54 (2): 461–467, 1981.PubMedGoogle Scholar
  52. 44.
    Kornblith PL, Smith BH, Leonard LA: Response of cultured human brain tumors to nitrosoureas. Correlation with clinical data. Cancer 47 (2): 255–265, 1981.PubMedGoogle Scholar
  53. 45.
    Schiffer D, Giordana MT, Pezzotta S, Paoletti P: Chemotherapeutic effects of some alkylating derivatives of nitrosourea on the development of tumors transplacentally induced in rats by E.N.U.: Acta Neuropath (Berl) 34 (1): 21–31, 1976.Google Scholar
  54. 46.
    Mealey Jr J, Chen TT, Shupe R: Response of cultured human glioblastomas to radiation and BCNU chemotherapy. J Neurosurg 41 (9): 339–349, 1974.PubMedGoogle Scholar
  55. 47.
    Searle J, Bawson TA, Abbott PJ, Harmon B, Kerr JFR: An electron microscopical study of the m ode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Path (Edinbg) 116 (2): 129–138, 1975.Google Scholar
  56. 48.
    Woo KB, Brenkus LB, Wilg KM: Analysis of the effects of antitumor drugs on cell cycle kinetics. Cancer Chemother Rep 59 (4): 847–860, 1975.PubMedGoogle Scholar
  57. 49.
    Rubinstein LJ: Tumors of the central nervous system. Atlas of Tumor Pathology, 2nd ser., Fasc. 6, Washington, DC.: Armed Forces Institute of Pathology, 1972.Google Scholar
  58. 50.
    Altmann HW, Müller HA: Grundlagen der Karyologie. Verh dtsch Ges Path 57: 2–33, 1973.Google Scholar
  59. 51.
    Jellinger K: Glioblastoma multiforme. Acta Neurochir 42 (l): 5–32, 1978.Google Scholar
  60. 52.
    Schiffer D, Giordana MT, Buoncristiani P, Paoletti P: Human malignant gliomas treated with chemotherapy: a pathological study Neurosurg 3 (l): 344–347, 1978.Google Scholar
  61. 53.
    Schiffer D, Giordana MT, Paoletti P, Soffietti R, Tarenzi T: Pathology of human malignant gliomas after radiation and chemotherapy. Acta Neurochir 53 (3–4): 205–216, 1980.Google Scholar
  62. 53a.
    Schiffer D, Giordana MT, Soffiett R, Sciolla R: Histological observations on the regrowth of malignant gliomas after radiotherapy and chemotherapy. Acta neuropath 58: 291–299, 1982.PubMedGoogle Scholar
  63. 54.
    Willson N, Duffy PE: Morphologic changes associated with combined BCNU and radiation therapy in glioblastoma multiforme. Neurology (Minneap) 24 (1): 465–471, 1974.Google Scholar
  64. 55.
    Gerstner L, Jellinger K, Heiss WD, Wöber G: Morphological changes in anaplastic gliomas treated with radiation and chemotherapy. Acta Neurochir 36 (2): 117–138, 1977.Google Scholar
  65. 56.
    Hoshino T, Wilson CB, Ellis WG: Gemistocytic astrocytes in gliomas. An autoradiographic study. J Neuropath Exp Neurol 34: 263–281, 1975.PubMedGoogle Scholar
  66. 57.
    Budka H, Podreka I, Zaunbauer F: Overgrowth of a primitive cell population in operated recurrent gliomas: the possible role of chemo- and radiotherapy. In: Paoletti P, Walker MD et al. (eds). Multidisciplinary aspects of brain Tumor Therapy. Elsevier/North Holland 1979, pp 357–362.Google Scholar
  67. 58.
    Burger PC, Mahaley MS, Dudka L, Vogel FS: The morphologic effects of radiation ad-ministered therapeutically for intracranial gliomas. Cancer 44 (5): 1256–1272, 1979.PubMedGoogle Scholar
  68. 59.
    Jellinger K: Human central nervous system lesions following radiation therapy. Zbl Neurochir 38 (3): 199–220, 1977.Google Scholar
  69. 60.
    Poisson M, Hauw J J, Pouillart P, Bataini JP, Mashaly R, Pertuiset BF, Metzger J: Malignant gliomas treated after surgery by combination chemotherapy and delayed irradiation. Acta Neurochir 31 (1): 27–42, 1979.Google Scholar
  70. 61.
    Vole D, Jellinger K, Flament H, Böck P, Klumair J: Cerebral space-occupying cysts following radiation and chemotherapy of malignant gliomas. Acta Neurochir 57 (3–4): 177–193, 1981.Google Scholar
  71. 61a.
    Seiler RW: Late results of multimodality therapy of high-grade supratentorial astrozytomas. Surg Neurol 15(2)88–91, 1981.PubMedGoogle Scholar
  72. 61b.
    Lieberman AN, Foo SH, Ransohoff J, Wise A, George A et al: Long term survival among pa¬tients with malignant brain tumors. Neurosurgery 19(4)450–453, 1982.Google Scholar
  73. 62.
    Pizzo PA, Poplack DG, Bleyer WA: Neurotoxicities of current leukemia therapy. Amer J Pediatr Hematol 1 (2): 127–140, 1979.Google Scholar
  74. 63.
    Bleyer WA, Griffin TW: White matter necrosis, mineralizing microangiopathy, and intellectual abilities in survivors of childhood leukemia: Associations of CNS irradiation and methotrexate therapy. In: Gilbert HA, Kagan AR (eds) Radiation Damage to the Nervous System. New York: Raven Press 1980, pp 155–174.Google Scholar
  75. 63a.
    Bleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: A new classification. Cancer Treatm Rep 65, Suppl 1, 89–98, 1981.Google Scholar
  76. 64.
    Hanefeld F, Riehm H: Therapy of acute lymphoblastic leukaemia in childhood: Effects on the nervous system. Neuropaediat 11 (1): 3–16, 1980.Google Scholar
  77. 65.
    Duttera MJ, Bleyer WA, Pomeroy TC, Leventhal CM, Leventhal BG: Irradiation, methotrexate toxicity, and the treatment of meningeal leukemia. Lancet II, 703–707, 1973.Google Scholar
  78. 66.
    Kölmel HW: Die intrathekale Gabe von Zytostatika. Nervenarzt 49 (6): 685–696, 1978.PubMedGoogle Scholar
  79. 67.
    Mott MG, Stevenson P, Wood CBD: Methotrexate meningitis. Lancet 2: 656, 1972.PubMedGoogle Scholar
  80. 68.
    Haghbin M: Antimetabolites in the prophylaxis and treatment of CNS leukemia. Cancer Treat Rep 61 (4): 681–687, 1977.Google Scholar
  81. 69.
    Davies-Jones GAB, Preston FE, Timperley WR: Neurological complications in Clinical Haematology. London: Black well 1980.Google Scholar
  82. 70.
    Aur RJA, Hustu HO, Verzosa MS et al: Comparison of two methods of preventing CNS leukemia. Blood 42 (3): 349–357, 1973.PubMedGoogle Scholar
  83. 71.
    Hustu HO, Aur RJA, Verzosa JP et al: Prevention of central nervous system leukemia by irradiation. Cancer 32 (7): 585–597, 1973.PubMedGoogle Scholar
  84. 72.
    Jellinger K, Budka H: Leukosen und maligne Lymphome. In: Dommasch D, Mertens HG (eds) Cerebrospinalflüssigkeit, CSF. Stuttgart: G. Thieme 1980, pp 34–40.Google Scholar
  85. 73.
    Peter A: Submicroscopic changes in leukemic cells of cerebrospinal fluid following intrathecal methotrexate. Acta Neuropath 29 (4): 345–352, 1974.PubMedGoogle Scholar
  86. 74.
    Budka HM, Guseo A, Jellinger K, Mittermayer K: Intermittent meningitic reaction with severe basophilia and eosinophilia in CNS leukemia. J Neurol Sei 28 (4): 459–468, 1976.Google Scholar
  87. 75.
    Glasser L, Corrigan J J, Payne C: Basophilic meningitis secondary to lymphoma. Neurology (Minneap) 26 (9): 899–902, 1976.Google Scholar
  88. 76.
    Campbell RH A, Marshall WC, Chessels JM: Neurological complications of childhood leukemia. Arch Dis Childh 52: 850–854, 1977.PubMedGoogle Scholar
  89. 76a.
    Williams SA, Makker SP, Grupe WE: Seizures: a significant side effect of chlorambucil therapy in children. J Pediatr 93: 516–518, 1978.PubMedGoogle Scholar
  90. 77.
    O’Callaghan M, Ekert H: Vincristine toxicity related to dose. Arch Dis Childh 51 (3): 289–293, 1976.PubMedGoogle Scholar
  91. 78.
    Dietrich E, Goebel B, Gutjahr P: EEG-Befunde nach Vincristin-Behandlung. Mschr Kinderheilk 126 (7): 709–712, 1978.Google Scholar
  92. 79.
    Carpenter LI, Lockhart LM: Ataxia and athetosis as side effects of chemotherapy with vin-cristine in non-Hodgkin lymphoma. Cancer Treatm Rep 62 (5): 561–562, 1978.Google Scholar
  93. 80.
    Allen JC, Rosen G. Transient cerebral dysfunction following chemotherapy for osteogenic sar¬coma. Ann Neurol 3 (4): 441–444, 1978.PubMedGoogle Scholar
  94. 81.
    Jean R, Navarro M, Marty M et al: Encéphalopathie aigue au cours du traitement des lym-phoblastoses de l’enfant. Ann pediatr 23 (7): 789–802, 1976.Google Scholar
  95. 81a.
    Berman I J, Mann MP: Seizures and transient cortical blindness associated with Cis-platinum (II) diamminedichloride (PDD) therapy. Cancer 45: 764–766, 1980.PubMedGoogle Scholar
  96. 82.
    Koenig H, Patel A: Biochemical basis of the acute cerebellar syndrome in 5-fluorouracil chemotherapy. Trans Am Neurol Assn 94: 290–292, 1972.Google Scholar
  97. 82a.
    Woodcock TM, Martin DS, Damin LAM et al: Combination clinical trials with thymidine and fluorouracil. Cancer 45: 1135–1143, 1980.PubMedGoogle Scholar
  98. 83.
    Price RA, Jamieson PA: The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer 35 (2): 306–318, 1975.PubMedGoogle Scholar
  99. 84.
    Mcintosh S, Aspnes GT: Encephalopathy following CNS prophylaxis in childhood lym-phoblastic leukemia. J Pediatr 91: 909–913, 1973.Google Scholar
  100. 85.
    Meadows AT, Evans AE: Effects of chemotherapy on the CNS. A study of parenteral MTX in long-term survivors of leukemia and lymphoma in childhood. Cancer 37 (4): 1079–1085, 1976.PubMedGoogle Scholar
  101. 86.
    Fusner J, Poplack DG, Pizzo PA, DiChiro G: Leukoencephalopathy following chemotherapy for rhabdomyosarcoma, reversibility of cerebral changes demonstrated by CT. J Pediat 91 (1): 77–79, 1977.PubMedGoogle Scholar
  102. 87.
    Mcintosh S, Klastkin EH, O-Brien RT, Aspnes GT, Klammerer BL et al. Chronic neurologic disturbance in childhood leukemia. Cancer 37 (6): 853–857, 1976.PubMedGoogle Scholar
  103. 88.
    Eiser C: Intellectual abilities among survivors of childhood leukemia as a functions of CNS irradiation. Arch Dis Childh 53 (4): 391–395, 1978.PubMedGoogle Scholar
  104. 89.
    Bleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. New Engl J Med 289: 770–773, 1973.PubMedGoogle Scholar
  105. 90.
    Kay HEM, Knapton PJ, O’Sullivan JP, Wells DG, Harris RF et al. Encephalopathy in acute leukemia associated with methotrexate therapy. Arch Dis Childh 47 (4): 344–354, 1972.PubMedGoogle Scholar
  106. 90a.
    Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ: Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 48: 2577–2582, 1981.PubMedGoogle Scholar
  107. 91.
    Terheggen HG, Rado M. Cerebrale Komplikationen der Leukämiebehandlung. I. Das Apathiesyndrom Mschr Kinderheilk 126: 693–695, 1978.Google Scholar
  108. 91a.
    Chien LT, Aur RJA, Stagner S, Cavallo K. et al.: Long-term neurological implications of somnolence syndrome in children with acute lymphocytic leukemia. Ann Neurol 8: 273–277, 1980.Google Scholar
  109. 92.
    Freeman JE, Johnston PGB, Voke JM: Somnolence after prophylactic cranial irradiation in children with acute lymphoblastic leukemia. Brit Med J 4: 523–525, 1973.PubMedGoogle Scholar
  110. 93.
    Olift A, Bleyer WA,Poplack DG: Acute encephalopathy after initiation of cranial irradiation for meningeal leukemia. Lancet 2: 13–15, 1978.Google Scholar
  111. 94.
    Garwicz S, Aronson AS, Elmqvist D, Landberg T: Postirradiation syndrome and EEG findings in children with acute lymphoblastic leukaemia. Acta Paediat Scand 64: 399–403, 1975.PubMedGoogle Scholar
  112. 95.
    Hendlin B, De Vivo DC, Torack R, Lell ME, Ragab AH, Vietti TJ: Parenchymatous degeneration of the central nervous system in childhood leukemia. Cancer 33 (2): 468–482, 1974.Google Scholar
  113. 96.
    Rubinstein LJ, Herman MM, Long TF, Wilburg JR: Disseminated necrotizing leukoencephalopathy: A complication of treated central nervous system leukemia and lymphoma. Cancer 35 (2): 291–305, 1975.PubMedGoogle Scholar
  114. 97.
    Wendling LR, Bleyer WA, DiChiro G, Mcllvanie SK: Transient severe periventricular hypoden- sity after leukemia prophylaxis with cranial irradiation and intrathecal methotrexate. J Comp Ass Tomogr 2: 502–505, 1978.Google Scholar
  115. 98.
    Shapiro WR, Posner JG: Chronic methotrexate toxicity in the CNS. Clin Bull 10 (1): 49–52, 1980.PubMedGoogle Scholar
  116. 99.
    Aur RJA, Simone JV, Verzosa MS, Hustu HO, Pinkel DP, Barker LF. Leucoencefalopatia en ninos con leucemia linfocitica aguda sometidos a terapeutica preventiva del sistema nervioso central. Sngre 23 (1): 1–12, 1977.Google Scholar
  117. 99a.
    Simone JV: Late complications of treatment of children with leukemia and lymphoma. Bristol-Myers Cancer Symposia, Vol. 3, p 663. New York: Academic Press, 1982.Google Scholar
  118. 100.
    DeVivo DC, Malas D, Nelson JS, Land VJ: Leukoencephalopathy in childhood leukemia. Neurology (Minneap) 27 (7): 609–613, 1977.Google Scholar
  119. 101.
    Rosemberg S: La leucoencéphalopathie, complications du traitement des leucémies infantiles. Arch Franç Pédiat 36 (3): 291–297, 1979.PubMedGoogle Scholar
  120. 102.
    Liu HM, Maurer HS, Vongsvivut S, Conway J J: Methotrexate encephalopathy. A neuropathologic study. Human Path 9 (6): 635–648, 1978.Google Scholar
  121. 103.
    Ebels EJ: Iatrogenic damage to the CNS in malignant systemic disease. Acta Neuropath (Berl) Suppl VII: 352–355, 1981.Google Scholar
  122. 104.
    Aur RJA, Simone JV, Verzosa MS, Hustu MD, Barker LF, Pinkel DP et al: Childhood acute leukemia — Study III. Cancer 42 (6): 2123–2129, 1978.PubMedGoogle Scholar
  123. 105.
    Bresnan MD, Gilles FH, Lorenzo AV, Watters GV, Barlow CF: Leukoencephalopathy following combined irradiation and intraventricular MTX therapy of brain tumors in childhood. Trans. Amer Neurol Assn 97: 204–206, 1972.Google Scholar
  124. 106.
    Norrell H, Wilson CB, Slagel DE, Clark DB: Leukoencephalopathy following the administration of methotrexate into the cerebrospinal fluid in the treatment of primary brain tumors. Cancer 33 (4): 923–932, 1974.PubMedGoogle Scholar
  125. 107.
    Shapiro WR, Chernik NL, Posner JB. Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch Neurol (Chic) 28 (2): 96–102, 1973.Google Scholar
  126. 108.
    Breuer AC, Blank NK, Schoene WC: Multifocal pontine lesions in cancer patients treated with chemotherapy and CNS radiotherapy Cance 41 (6): 2112–2120, 1978.Google Scholar
  127. 109.
    Pratt RA: Cerebral necrosis following irradiation and chemotherapy for metastatic choriocarcinoma. Surg Neurol 7 (3): 117–120, 1977.PubMedGoogle Scholar
  128. 110.
    Garcia JH, Sandbank U, Gutin P: Multifocal leukoencephalopathy in adult leukemia: Histologic features and etiologic considerations. Acta Neuropath 40 (3): 273–276, 1977.PubMedGoogle Scholar
  129. 110a.
    Mena H, Garcia JH, Valandia F: Central and peripheral myelinopathy associated with systemic neoplasia and chemotherapy. Cancer 48: 1724–1737, 1981.PubMedGoogle Scholar
  130. 111.
    Nakazato Y, Ishida Y, Morimatsu M: Disseminated necrotizing leukoencephalopathy. Acta pathol Jap 30 /4, 659–670, 1980.Google Scholar
  131. 112.
    Skullerud K, Halvorsen K: Encephalomyelopathy following intrathecal methotrexate treatment in a child with acute leukemia. Cancer 42 (3): 1211–1215, 1978.PubMedGoogle Scholar
  132. 113.
    Allen JC, Rosen G, Mehta BM: Leukoencephalopathy following high-dose intravenous methotrexate chemotherapy with citro vorum factor rescue (abst). Ann Neurol 6: 179, 1979.Google Scholar
  133. 114.
    Rosen G, Ghavine F, Nirenberg A, Mosende C, Mehta BM: High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children. Cancer Treat Rep 62 (00): 681–680, 1977.Google Scholar
  134. 114a.
    Schold SC, Fay JW: Central nervous system toxicity from high-dose BCNU treatment of systemic cancer. Neurology 30: 429, 1980.Google Scholar
  135. 115.
    Patterson AH: Possible neurologic complications of DTIC. Cancer Treat Rep 61 (2): 105–106, 1977.Google Scholar
  136. 116.
    Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos A: Primary osteogenic sarcoma. Rationale for preoperative chemotherapy and delayed surgery. Cancer 43 (7): 2163–2177, 1979.PubMedGoogle Scholar
  137. 117.
    Soni SS, Marten GW, Pitner SE, Dueñas DA, Pawozek M: Effects of central nervous system irradiation on neuropsychologic functioning of children with acute lymphocytic leukemia. New Engl J Med 293 (2): 113–118, 1975.PubMedGoogle Scholar
  138. 118.
    Verzosa MS, Aur RJA, Simone JV, Hustu HO, Pinkel DP: Five years after central nervous system irradiation of children with leukemia. Int J Radiat Oncol Biol Psych 1 (2): 209–215, 1976.Google Scholar
  139. 119.
    Simone JV, Aur RJA, Hustu HD, Verzosa MS, Pinkel DP: Three to ten years after cessation of therapy in children with leukemia. Cancaer 42 (3): 839–845, 1978.Google Scholar
  140. 120.
    Hübener KH, Treuner J, Voss AC, Metzger HOF: Spätfolgen präventiver Strahlen- und Chemotherapie des Hirnschädels bei Kindern mit akuter Leukämie Strahlenther 156 (1): 26–29, 1980.Google Scholar
  141. 121.
    Arnold H, Kühne D, Franke H, Grosch I: Findings in CAT after intrathecal methotrexate and radiation. Neuroradiol 16 (1): 65–68, 1978.Google Scholar
  142. 122.
    Peylan-Ramu N, Poplack DG, Bley CL, Herdt JR, Vermess M, Dichiro G: CAT in methotrex-ate encephalopathy. J Comp Ass Tomogr 1 (4): 437–442, 1977.Google Scholar
  143. 122a.
    Peylan-Ramu N, Poplack OG, Pizzo PA, Adornato BT, DiChiro G: Abnormal CT scans in asymptomatic children with ALL after prophylactic treatment of the CNS with radiation and intrathecal chemotherapy. New Engl J Med 298: 815–818, 1978.PubMedGoogle Scholar
  144. 123.
    Kingsley DPE, Kendall BE: Cranial computed tomography in leukemia. Neuroradiol 16 (6): 543–546, 1978.Google Scholar
  145. 124.
    Enzmann DR, Lane B: Enlargement of subarachnoid spaces and lateral ventricles in pediatric patients undergoing chemotherapy. J Pediatr 92: 535–539, 1978.PubMedGoogle Scholar
  146. 125.
    Gastaut JA, Gastaut JL, Carcassonne Y: Computerized acial tomography in the study of in-tracranial complications in hematology. Cancer 21 (2): 487–501, 1978.Google Scholar
  147. 126.
    Treuner J, Hübner KH, Böhmer H, Küpper U: Auffällige CT-Befunde des Schädels nach präventiver ZNS-Behandlung akuter Leukämien bei Kindern. Onkologie 2 (1): 83–86, 1979.PubMedGoogle Scholar
  148. 126a.
    Shalen PR, Ostrow PT, Glass PJ: Enhancement of the white matter following prophylactic therapy of the CNS for leukemia: Radiation effects and methotrexate leukoencephalopathy. Radiology 140: 409–412, 1981.PubMedGoogle Scholar
  149. 127.
    Day RE, Kingston J, Bullimore JJ, Mott MG, Thomson JLG: CAT brain scans after CNS prophylaxis for ALL. Brit Med J 2: 6154, 1978.Google Scholar
  150. 128.
    Kretzschmar K, Gutjahr P, Kutzner J: CT studies before and after CNS treatment for ALL and malignant Non-Hodgkin’s lymphoma in childhood. Neuradiol 20 (2): 173–180, 1980.Google Scholar
  151. 129.
    Ochs JJ, Berger MM, Brecher ML, Sinks LS, Kinkel W, Freeman AI: CT brain scans in children with ALL receiving methotrexate alone as CNS prophylaxis. Cancer 45 (9): 2274–2278, 1980.PubMedGoogle Scholar
  152. 130.
    DeReuck JL, Sieben GJ, Sieben-Praet MR, Ngendakayo P et al: Wernicke’s encephalopathy in patients with tumors of the lymphoid-hemopoietic system. Arch Neurol (Chic) 37 (3): 338–341, 1980.Google Scholar
  153. 131.
    Gangji D, Reaman GH, Cohen SR, Bleyer WA et al: Elevated basic myelin protein in the CSF of ALL patients with leukoencephalopathy. Proc Amer Ass Cancer Res Amer Assoc Clin On-col 20: 353, 1979.Google Scholar
  154. 132.
    Iinuma K, Hayashi T, Ikuta F: Disseminated necrotizing leukoencephalopathy accompanied with calcium following antineoplastic therapy in a case with ALL. Adv Neurol Sei (Tokyo) 21 (2): 190–197, 1977.Google Scholar
  155. 133.
    Koga S, Fijimoto T, Hasegawa K, Sueishi K: Disseminated necrotizing leukoencephalopathy following intrathecal methotrexate. Fukuoka Igaku Zasski 67 (1): 64–71, 1976.Google Scholar
  156. 134.
    Morimatsu M, Hirai S, Ogawa S, Motegi M, Nakazato Y: A case of disseminated necrotizing leukoencephalopathy associated with intrathecal methotrexate therapy. Neurol Med (Tokyo) 9 (1): 54–62, 1978.Google Scholar
  157. 135.
    Verity MA, Wolfson WL: Cerebral lymphomatoid granulomatosis. A report of two cases, with disseminated necrotizing leukoencephalopathy. Acta Neuropath 36 (2): 117–124, 1976.PubMedGoogle Scholar
  158. 136.
    Rosemberg S: Encephalopathie apparve au cours d’un traitement par la vincristine. Arch franc Pediat 31 (4): 391–398, 1974.PubMedGoogle Scholar
  159. 137.
    Crosley CJ, Rorke LB, Evans A, Nigro M: Central nervous system lesions in childhood leukemia. Neurology 28 (7): 678–685, 1978.PubMedGoogle Scholar
  160. 138.
    Jellinger K, Radaszkiewicz TH: Involvement of the central nervous system in malignant lymphomas. Virch Arch Abt A Path Anat 370 (4): 345–362, 1976.Google Scholar
  161. 139.
    Moir DH, Bale PM: Necropsy findings in childhood leukemia. Pathology 8: 247–258, 1978.Google Scholar
  162. 140.
    Borns PF, Rancier LF: Cerebral calcification in childhood leukemia mimicking Sturge-Weber syndrome. Amer J Roentg 122 (1): 52–55, 1974.Google Scholar
  163. 141.
    Mueller S, Bell W, Seibert J: Cerebral calcifications associated with intrathecal methotrexate therapy in ALL. J Pediatr 88 (4): 650–653, 1976.PubMedGoogle Scholar
  164. 142.
    Mcintosh S, Fisher DB, Rothman S, Rosenfield N, Lobel JS, O’Brien RT: Intracranial calcifications in childhood leukemia. J Pediatr 91: 909–913, 1977.PubMedGoogle Scholar
  165. 143.
    Flament-Durand J, Ketelbant-Balasse P, Maurus R, Regnier R, Spehl M: Intracerebral calcifications appearing during the course of ALL treated with methotrexate and X rays. Cancer 35 (2): 319–325, 1975.PubMedGoogle Scholar
  166. 144.
    Price RA, Birdwell DA: The central nervous system in childhood leukemia. III. Mineralizing microangiopathy and dystrophic calcification. Cancer 42 (2): 717–728, 1978.PubMedGoogle Scholar
  167. 145.
    Michotte Y, Smeyers-Verbeke J, Ebinger G, Maurus R, Pelsmaekers J et al: Brain calcification in a case of acute lymphoblastic leukemia. J Neurol Sei 25 (2): 145–152, 1975.Google Scholar
  168. 146.
    Rosman NP, Kakulas BA, Richardson EP: Central pontime myelinolysis in a child with leukemia. Arch Neurol (Chic) 14 (3): 273–280, 1966.Google Scholar
  169. 147.
    Cadman TE, Rorke LE: Central pontine myelinolysis in childhood and adolescence. Arch Dis Childh 44 (2): 342–350, 1969.PubMedGoogle Scholar
  170. 148.
    Minauf M, Krepier P: Zentrale pontine Myelinolyse bei einem Kind mit Leukämie. Arch Kinderheilk 180 (1): 55–65, 1969.PubMedGoogle Scholar
  171. 149.
    Valsamis MP, Peress NS, Wright LD: Central pontine myelinolysis in childhood. Arch Neurol (Chic) 26: 307–312, 1971.Google Scholar
  172. 150.
    Goebel HH, Herman-Ben Zur P: Central myelinolysis. In: Handbook of Clinical Neurology, Vinken PJ, Bruyn GW (eds). Vol. 28, Amsterdam-Oxford-New York; Elsevier/North Holland 1976, pp 285–316.Google Scholar
  173. 151.
    Sah N, Wolff JA: Thiamine deficiency: probable Wernicke’s encephalopathy successfully treated in a child with ALL. Pediatrics 51: 750–751, 1973.Google Scholar
  174. 152.
    Reuck J de, Sieben G, Coster W de, Van der Eecken H: Prospective neuropathologic study on the occurrence of Wernicke’s encephalopathy in patients with tumours of the lymphoid-hemopoietic system. Acta Neuropath Suppl VII, 356–358, 1981.Google Scholar
  175. 153.
    Bowles D, Allen JC, Rosen G: Normal CT of the brain in osteosarcoma patients treated with high-dose methotrexate. Cancer 47: 1762–1765, 1981.PubMedGoogle Scholar
  176. 154.
    Moore EW, Thomas LB, Shaw RK, Freireich EJ: The central nervous system in acute leukemia. Arch Intern Med 105 (2): 141–158, 1960.Google Scholar
  177. 155.
    Reuck J de, Coster W de, Van der Eecken H: Communicating hydrocephalus in treated leukemic patients. Europ Neurol 18 (1): 8–14, 1979.PubMedGoogle Scholar
  178. 156.
    Schochet SS, Lampert PW, Earle KM: Neuronal changes induced by intrathecal vincristine sulfate. J Neuropath Exp Neurol 27 (4): 645–658, 1968.PubMedGoogle Scholar
  179. 157.
    Shepherd DA, Steuber CP, Starling KA et al: Accidental intrathecal administration of vin-cristine. Med Pediatr Oncol 5 (1): 85–88, 1978.PubMedGoogle Scholar
  180. 158.
    Slyter H, Liwnicz B, Herrick MK, Mason R: Fatal myeloencephalopathy caused by intrathecal vincristine. Arch Neurol (Chic) 30 (8): 867–871, 1980.Google Scholar
  181. 159.
    Sullivan MP, Vietti TJ, Fernbach DJ, Griffith KM, Haddy TB, Watkins LW: Clinical investigations in the treatment of meningeal leukemia: radiation therapy regimens vs conventional intrathecal methotrexate. Blood 34 (3): 301–319, 1966.Google Scholar
  182. 160.
    Back EH: Death after intrathecal methotrexate. Lancet 2: 1005, 1969.PubMedGoogle Scholar
  183. 161.
    Bagshawe KD, Magrath IT, Golding PR: Intrathecal methotrexate. Lancet 2: 1258, 1969.PubMedGoogle Scholar
  184. 162.
    Pasquinacci G, Pardini R, Fedi F: Intrathecal methotrexate. Lancet 1: 309–310, 1970.Google Scholar
  185. 163.
    Baum ES, Koch HF, Corby DG, Plunket DC: Intrathecal methotrexate. Lancet 1: 649, 1971.PubMedGoogle Scholar
  186. 164.
    Pouillart P, Schwarzenberg L, Schneider M, Amiel JL, Mathé G: Les méningitis lympho-blastiques. Presse Méd 1; 387–381, 1971.Google Scholar
  187. 165.
    Thompson SW, Saiki J, Kornfeld M et al: Paraplegia following intrathecal antileukemic therapy. Neurology (Minneap) 21: 454, 1971.Google Scholar
  188. 166.
    Bernard J, Boiron M, Jacquillat C, Schaison G, Weil M: Traitement des leucémies aiguës. Rapp XXIIIe Congr Ass Pédiatr Lange Franç Vol. III, 1972, p 367.Google Scholar
  189. 167.
    Saiki JH, Thompson S, Smith F, Atkinson R: Paraplegia following intrathecal chemotherapy. Cancer 29: 370–374, 1972.PubMedGoogle Scholar
  190. 167a.
    Gutin PH, Levi JA, Wiernik PH et al.: Treatment of malignant meningeal disease with in-trathecal Thiotepa. Cancer Treatm Rep 61: 885–887, 1977.Google Scholar
  191. 168.
    Luddy RE, Gilman PA: Paraplegia following intrathecal methotrexate. J Pediatr 83: 988–992, 1973.PubMedGoogle Scholar
  192. 169.
    Corberand J, Pris J, Robert A, Monnier J, Regnier C: Accidents neurologiques graves secondaires à l’injection intra-rachidienne d’agents cytostatiques. Arch franç Pédiat 30 (5): 177–188, 1973.PubMedGoogle Scholar
  193. 170.
    Gagliano RG, Costanzi JJ: Paraplegia following intrathecal methotrexate. Cancer 37: 1663–1668, 1976.PubMedGoogle Scholar
  194. 171.
    Meyer R, Bergerat JP, Lang JM, Oberling T: Accident neurologique mortel après méthotrexate intrarachidien. Neuv Presse méd 5: 149–151, 1976.Google Scholar
  195. 172.
    Tomonaga M, Takeno Y, Ishii N, Okayama M: Paraplegia following intrathecal methotrexate, Adv Neurol Sei (Tokyo) 22: 1204–1211, 1978.Google Scholar
  196. 173.
    Reznik M: Acute ascending poliomyelomalacia after treatment of acute lymphocytic leukemia. Acta Neuropathol (Berl) 45 (2): 153–157, 1979.Google Scholar
  197. 174.
    Grisold W, Lutz D, Wolf D: Necrotizing myelopathy associated with acute lymphatic leukemia. Acta Neuropath 49 (3): 321–235, 1980.Google Scholar
  198. 175.
    Breuer AC, Pitman SW, Dawson DM, Schoene WC: Paraparesis following intrathecal cytosine arabinoside. Cancer 40 (6): 2817–2822, 1977.PubMedGoogle Scholar
  199. 176.
    Wisniewski H, Shelanski MI, Terry RD: Effects of mitotic spindle inhibitor on neurotubules and neurofilaments in anterior horn cells. J Cell Biol 38 (3): 224–229, 1968.PubMedGoogle Scholar
  200. 177.
    Goldie JH, Price LA, Harrap KR: Methotrexate toxicity. Correlation with duration of ad-ministration; plasma levels and excretion pattern. Europ J Cancer 8: 409–414, 1972.Google Scholar
  201. 178.
    Ettinger LJ, Freeman AI, Creaven PJ: Intrathecal methotrexate overdose without neurotoxicity. Cancer 41 (4): 1270–1273, 1978.PubMedGoogle Scholar
  202. 179.
    Lampkin BC, Higgins GR, Hammond D: Absence of neurotoxicity following massive intrathecal administration of methotrexate. Case report. Cancer 20 (5): 1780–1781, 1967.PubMedGoogle Scholar
  203. 180.
    Phillips TL, Fu KK: Quantification of combined radiation therapy and chemotherapy effects of critical normal tissues. Cancer 37: 1186–1200, 1976.PubMedGoogle Scholar
  204. 181.
    Rosen G, Tefft M, Martinez A, Chan W, Murphy ML: Combination chemotherapy and radiation therapy in the treatment of metastatic osteogenic sarcoma. Cancer 35 (3): 622–639, 1975.PubMedGoogle Scholar
  205. 182.
    Griffin TW, Rasey JS, Bleyer WA: The effect of photon irradiation on blood-brain barrier permeability to methotrexate in mice. Cancer 40 (5): 1109–1111, 1977.PubMedGoogle Scholar
  206. 183.
    Neuwelt EA, Frenkel EP, Barnett HP, Maravilla KR, Rapoport S: Osmotic blood-brain barrier disruption: Computerized tomographic scanning of chemotherapeutic agent delivery. Ann Neurol 6 (2): 166, 1979.Google Scholar
  207. 184.
    Kelley JM, Asbury AK, King JS: Neuropathologic effects of intrathecal water. J Neuropath Exp Neurol 34 (2): 388–000, 1975.Google Scholar
  208. 185.
    Bunge PR, Settlage PH: Neurological lesions in cats following cerebrospinal fluid manipulation. J Neuropath Exp Neurol 16 (3): 471–482, 1957.PubMedGoogle Scholar
  209. 186.
    Shelanski ML, Feit H: Filaments and tubules in the nervous system. In: Bourne GH (ed): The Structure and Function of Nervous Tissue. New York: Academic Press 1972, Vol. 5, pp 47–80.Google Scholar
  210. 187.
    Craft WA, Reid MM, Bruce E, Kernahan J, Gardner PS: Role of infection in the death of children with ALL. Arch Dis Childh 52: 752–757, 1977.PubMedGoogle Scholar
  211. 188.
    Bell WE, McCormick WF: Neurologic Infections in Children, Second edition, Philadelphia: Saunders, 1981.Google Scholar
  212. 189.
    Townsend JJ, Wolinsky JS, Baringer JR, Johnson PC: Acquired toxoplasmosis. A neglected cause of treatable nervous system disease. Arch Neurol 23: 335–343, 1975.Google Scholar
  213. 189a.
    Henson RA, Urich H: Cancer and the nervous system. London-Edinburgh-New York; Blackwell 1982.Google Scholar
  214. 189b.
    Cairncross JG, Posner JB: Neurological complications of malignant lymphomas. In: Vinken PJ, Bruyn GW (eds) Handbook of Clinical Neurology, Vol. 36. Amsterdam-New York: North Holland/Elsevier 1980, pp 27–62.Google Scholar
  215. 189c.
    Trump DL, Grossman SA, Thompson G, Murray K: CNS infections complicating the management of neoplastic meningitis. Arch. Intern Med. 142: 583–586, 1982.PubMedGoogle Scholar
  216. 190.
    Parker JC, McClaskey JJ, Lee RS: Human cerebral candidosis. A postmortem evaluation of 19 patients. Human Path 12 (1): 23–27, 1981.Google Scholar
  217. 191.
    Weenink HR, Bruyn GW: Cryptococcosis of the nervous system. In: Vinken PJ, Bruyn GW (eds) Handbook of Clinical Neurology, Amsterdam-New York-Oxford: Elsevier/North Holland, Vol. 35, 1978, pp 459–502.Google Scholar
  218. 192.
    Ruskin J, Remington JS: Toxoplasmosis in the compromised host. Ann Int Med 84 (2): 193–199, 1976.PubMedGoogle Scholar
  219. 193.
    Frenkel JK, Nelson BM, Arias-Stella J: Immunosuppression and toxoplasmic encephalitis. Clinical and experimental aspects. Human Path 6 (1): 97–111, 1975.Google Scholar
  220. 194.
    Astrom KE, Mancall EL, Richardson EF Jr: Progressive multifocal leukoencephalopathy: a hitherto unrecognized complication of chronic lymphatic leukemia and Hodgkin’s disease. Brain 81 (2): 93–111, 1958.PubMedGoogle Scholar
  221. 195.
    Walker DI: Progressive multifocal leukoencephalopathy: an opportunistic viral in infection of the central nervous system. In: Vinken PJ, Bruyn GW (eds) Handbook of Clinical Neurology. Amsterdam-New York-Oxford: North Holland/Elsvier, Vo. 34, pp 307–329, 1978Google Scholar
  222. 196.
    Peters ACB, Versteeg J, Bots GTAM, Boogerd W, Vielvoye J: Progressive multifocal leukoencephalopathy. Immunofluorescent demonstration of simian virus 40 antigen in CSF cells and response to cytarabine therapy. Arch Neurol (Chic) 37(4):497–980.Google Scholar
  223. 197.
    Castaigne P, Rondot P, Escourolle R, Ribadeau-Dumas JL, Cathala F, Hauw JJ: Leu- coencéphalopathie multifocale progressive et ‘gliomas’ multiples. Rev Neurol 130: 379–392, 1974.PubMedGoogle Scholar
  224. 198.
    GiaRusso MH, Koeppen AH; Atypical progressive multifocal leukoencephalopathy and primary cerebral malignant lymphoma. J Neurol Sei 35 (3): 394–398, 1978.Google Scholar
  225. 199.
    Ho KC, Garancis JC, Peagle RD, Gerber MA, Borkowski WJ: Progressive multifocal leukoencephalopathy and microglioma in a patient with immunosuppressive therapy. Acta Neuropath 52 (1): 81–83, 1980.PubMedGoogle Scholar
  226. 200.
    Lyon G: Examen ultrastructural du cerveau dans trois encephalopathies aiguës et chroniques au cours de déficits immunitaires. Arch franç Pédiatr 29 (00): 541–554, 1972.Google Scholar
  227. 201.
    Breitfeld Y, Yashida Y, Sherman FE, Odagiri K, Yunis EJ: Fatal measles infection in children with leukemia. Lab. Invest 28(3):279–291, 19743.Google Scholar
  228. 202.
    Sluga E, Budka H, Jellinger K, Pichler E: SSPE-like inclusion body disorder in treated childhood leukemia. Acta Neuropath Suppl VI: 267–272, 1975.Google Scholar
  229. 203.
    Pullan CR, Noble TC, Scott TJ, Wisniewski K, Gardner PS: Atypical measles infections in leukemic children on immunosuppressive treatment. Brit Med J 1: 1562–1565, 1976.PubMedGoogle Scholar
  230. 204.
    Smyth D, Tripp JH, Brett EM, Marshall WC, Almeida J, Dayan AD et al: Atypical measles encephalitis in leukemic children in remission. Lancet 2: 574, 1976.PubMedGoogle Scholar
  231. 205.
    Murphy JV, Yunis EJ: Encephalopathy following measles infection in children with chronic ill-ness. J Pedit 88: 937–942, 1976.Google Scholar
  232. 206.
    Drysdale HC, Jones LF, Oppenheimer DR, Tomlinson AH: Measles inclusion body encephalitis in a child with treated ALL. J Clin Path 29: 865–872, 1976.PubMedGoogle Scholar
  233. 207.
    Haltia M, Paetau A, Erkkilä H, Donner M, Kaakinen K, Holmström T: Fatal measles encephalopathy with retinopathy during cytotoxic chemotherapy. J Neurol Sei 32 (3): 323–330, 1977.Google Scholar
  234. 208.
    Aicardi J, Goutieres F, Arsenio-Nunes ML, Lebon P: Acute measles encephalitis in children with immunosuppression. Pediatrics 59: 232–239, 1977.PubMedGoogle Scholar
  235. 209.
    Wolinsky JS, Swoveland P, Johnson KP, Baringer JR: Subacute measles encephalitis complicating Hodgkin’s disease in an adult. Ann Neurol 1 (5): 452–457, 1977.PubMedGoogle Scholar
  236. 210.
    Campbell RHA, Marshall WC, Chessells JM: Neurological complication of childhood leukemia. Arch Dis Childh 52: 850–858, 1977.PubMedGoogle Scholar
  237. 211.
    Petersen FK, Schiotz PO, Valerins NH et al: Immunosuppressive measles encephalopathy. Acta Paediat Scand 67 (2): 109–112, 1978.Google Scholar
  238. 212.
    Spalke G, Eschenbach C: Infantile cortical measles inclusion body encephalitis during combined treatment of ALL. J Neurol 230 (3): 269–277, 1979.Google Scholar
  239. 213.
    Price R, Chernik NL, Horta-Barbosa L, Posner JB: Herpes simplex encephalitis in an anergic patient. Amer J Med 54 (3): 222–228, 1973.PubMedGoogle Scholar
  240. 214.
    Henderson BE, Ziegler JL, Templeton AC: Acute necrotizing encephalitis in a patient with Hodgkin’s disease. East Afr Med J 48: 592–600, 1971.PubMedGoogle Scholar
  241. 215.
    Dayan AD, Bhatti I, Gostling JVT: Encephalitis du to herpes simplex in a patient with treated carcinoma of the uterus. Neurology (Minneap) 17 (6): 609–613, 1967.Google Scholar
  242. 216.
    Dayan AD: Encephalitis due to simultaneous infection by herpes simplex and measles viruses. J Neurol Sei 14 (4): 315–323, 1971.Google Scholar
  243. 217.
    Mellor DH, Purcell M: Unusual encephalitic illness in a child with acute leukemia in remission. Possible role of measles virus and Toxoplasma gondii. Neuropaediatr 7 (4): 423–430, 1976.Google Scholar
  244. 218.
    Vuia O: Micronodular encephalitis and acute leukemia treated with immunosuppressives in a child. Neuropaed 6 (3): 307–312, 1975.Google Scholar
  245. 219.
    Casey EB, Jellife AM, Le Quesne PM, Millet YL: Vincristine neuropathy. Clinical and electrophysiological observations. Brain 96 (1): 69–86, 1973.PubMedGoogle Scholar
  246. 220.
    Rosenthal S, Kaufman S: Vincristine neurotoxicity. Ann Intern Med 80 (6): 733–737, 1974.PubMedGoogle Scholar
  247. 221.
    Sandler SG, Tobin W, Henderson ES: Vincristine-induced neuropathy. A clinical study of fifty patients. Neurology (Minneap) 19: 367–374, 1969.Google Scholar
  248. 222.
    Daun H, Hartwich G: Die Vincristin-Polyneuritis. Fortschr Neurol Psychiat 39 (3): 151–165, 1971.Google Scholar
  249. 223.
    Caccia MR: Vincristine polyneuropathy in man. J Neurol 216 (1): 21–26, 1977.PubMedGoogle Scholar
  250. 224.
    McLeod JG, Penny R: Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiat 32 (3): 297–304, 1969.PubMedGoogle Scholar
  251. 225.
    Heiss WD, Turnheim M, Mamoli B: Combination chemotherapy of malignant glioma. Effect of postoperative treatment with CCNU, vincristine amethopterine and procarbazine. Europ J Cancer 11: 1191–1202, 1978.Google Scholar
  252. 226.
    Watkins SM: High incidence of vincristine induced neuropathy in lymphomas. Brit Med J 1: 610–612, 1978.PubMedGoogle Scholar
  253. 227.
    Bradley WG, Lassman LP, Pearce GW, Walton JN: The neuromyopathy of vincristine in man. J Neurol Sci 10 (2): 107–131, 1970.PubMedGoogle Scholar
  254. 228.
    Bradley WG: The neuromyopathy of vincristine in the guinea pig. An electrophysiological and pathological study. J Neurol Sci 10 (2): 133–162, 1970.PubMedGoogle Scholar
  255. 229.
    Green LS, Donoso JA, Hallar-Bettinger IE, Samson FE: Axonal transport disturbances in vincristine-induced polyneuropathy. Ann Neurol 1 (3): 255–262, 1977.PubMedGoogle Scholar
  256. 230.
    Schlaepfer WW: Vincristine-induced axonalalterations in rat peripheral nerve. J Neurpath Exp Neurol 30 (3): 488–506, 1971.Google Scholar
  257. 231.
    Wulfhekel U, Diillmann J: Ein licht- und elektronenoptischer Beitrag zur Vinca-Alkaloid-Poly neuropathie. Virchows Arch Abt A Path Anat 357 (2): 163–178, 1972.Google Scholar
  258. 232.
    Obrist R, Paravicini U, Harmtann D et al.: Vindesine: a clinical trial with special reference to neurological side effects. Cancer Chemother Pharmacol 2: 233–237, 1979.PubMedGoogle Scholar
  259. 233.
    Botez MI, Peyronnard JM, Bachevealier J, Charron L: Polyneuropathy and folate deficiency. Arch Neurol (Chic) 35 (9): 581–584, 1978.Google Scholar
  260. 234.
    Hemphill M, Pestrank A, Walsh T. et al: Sensory neuropathy in Cis-platinum therapy. Neurology 30: 429, 1980.Google Scholar
  261. 235.
    Clark AW, Parhad IM, Griffin JW et al: Neurotoxicity of cis-platinum pathology of the central and peripheral nervous system. Neurology (NY) 30: 429, 1980.Google Scholar
  262. 236.
    Russell JA, Powles RL: Neuropathy due to cytosine arabinoside. Brit Med J 2: 652–653, 1974.Google Scholar
  263. 237.
    Clarke JTR, Karpati G, Carpenter S, Wolfe LS: The effect of vincristine on skeletal muscle in the rat. J Neuropath Exp Neurol 31 (3): 247–266, 1972.PubMedGoogle Scholar
  264. 238.
    Michalek JC, Dibella NH: Exacerbation of myotonic dystrophy by vincristine. New Engl J Med 295: 283–284, 1976.Google Scholar
  265. 239.
    Ho M, Bear RA, Garvey MB: Symptomatic hypophosphatemia secondary to 5-azacytidine therapy of acute non-lymphatic leukemia. Cancer Treatm Rep 60: 1400–1402, 1976.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston/The Hague/Dordrecht/Lancaster 1983

Authors and Affiliations

  • Kurt Jellinger

There are no affiliations available

Personalised recommendations